Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer.

Spring, Laura M; Han, Hyo; Liu, Minetta C; Hamilton, Erika; Irie, Hanna; Santa-Maria, Cesar A; Reeves, James; Pan, Peng; Shan, Ming; Tang, Yongqiang; Graham, Julie R; Hazard, Sebastien; Ellisen, Leif W; Isakoff, Steven J

Spring, Laura M; Han, Hyo; Liu, Minetta C; Hamilton, Erika; Irie, Hanna; Santa-Maria, Cesar A; Reeves, James; Pan, Peng; Shan, Ming; Tang, Yongqiang; Graham, Julie R; Hazard, Sebastien; Ellisen, Leif W; Isakoff, Steven J.

Afiliación

Spring LM; Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Han H; Moffitt Cancer Center-McKinley Outpatient Clinic, Tampa, FL, USA.
Liu MC; Mayo Clinic, Rochester, MN, USA.
Hamilton E; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.
Irie H; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Santa-Maria CA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Reeves J; Florida Cancer Specialists-South/Sarah Cannon Research Institute, Fort Myers, FL, USA.
Pan P; GSK, Waltham, MA, USA.
Shan M; EQRx, Cambridge, MA, USA.
Tang Y; GSK, Waltham, MA, USA.
Graham JR; Translational Discovery & Development, Boston Pharmaceuticals, Boston, MA, USA.
Hazard S; GSK, Waltham, MA, USA.
Ellisen LW; GSK, Waltham, MA, USA.
Isakoff SJ; Alkermes Incorporated, Waltham, MA, USA.

Nat Cancer ; 3(9): 1138, 2022 Sep.

Article en En | MEDLINE | ID: mdl-35931884

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Nat Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google